Skip to main content

Advertisement

Controversy Continues Over Muscular Dystrophy Drug, Despite FDA Approval

04:46
Duchenne muscular dystrophy patients Jack Willis (center), Nolan Willis (right) and Max LeClaire, attended the opening of Sarepta Therapeutics new headquarters in Cambridge, Mass., in 2014. (Boston Globe via Getty Images)
Duchenne muscular dystrophy patients Jack Willis (center), Nolan Willis (right) and Max LeClaire, attended the opening of Sarepta Therapeutics new headquarters in Cambridge, Mass., in 2014. (Boston Globe via Getty Images)

Advertisement

Advertisement

Listen Live